12798 Federal Register / Vol. 66, No. 40 / Wednesday, February 28, 2001 / Notices

1. Native American Bancorporation,

Co., Denver, Colorado; to engage

through Native American Community

Development Corporation, Denver,

Colorado, in community development

activities, pursuant to 12 CFR

225.28(b)(12).

Board of Governors of the Federal Reserve

System, February 22, 2001.

Robert deV. Frierson

Associate Secretary of the Board.

[FR Doc. 01–4808 Filed 2–27–01; 8:45 am]

BILLING CODE 6210–01–S

GOVERNMENT PRINTING OFFICE

Depository Library Council to the

Public Printer; Meeting

The Depository Library Council to the

Public Printer (DLC) will meet on

Sunday, April 1, 2001, through

Wednesday, April 4, 2001, in San

Antonio, Texas. The sessions will take

place from 7:30 p.m. until 10 p.m. on

Sunday, 8:30 a.m. until 5 p.m. on

Monday and Tuesday and from 8:30

a.m. until 3:30 p.m. on Wednesday. The

meeting will be held at the Adam’s

Mark San Antonio Riverwalk Hotel, 111

Pecan Street East, San Antonio, Texas.

The purpose of this meeting is to

discuss the Federal Depository Library

Program. All sessions are open to the

public.

A limited number of hotel rooms have

been reserved at the Adam’s Mark San

Antonio Riverwalk Hotel for anyone

needing hotel accommodations.

Telephone: 210–354–2800. Please

specify the U.S. Government Printing

Office when you contact the hotel.

Room cost per night is $91 (plus tax) per

night single and $115 (plus tax) per

night double, triple or quad through

March 5, 2001.

Michael F. DiMario,

Public Printer.

[FR Doc. 01–4855 Filed 2–27–01; 8:45 am]

BILLING CODE 1520–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Advisory Committee for Injury

Prevention and Control: Family and

Intimate Violence Prevention

Subcommittee: Conference Call

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following subcommittee

conference call.

Name: ACIPC Family and Intimate

Violence Prevention Subcommittee.

Times and Dates: 1 p.m.–3 p.m., March 12,

2001.

Place: National Center for Injury

Prevention and Control (NCIPC), Koger

Center—Vanderbilt Building, Conference

Room 2000, 2939 Flowers Road South,

Atlanta, Georgia 30341.

Status: Open to the public, limited only by

the space available.

Purpose: To provide and make

recommendations to ACIPC and the Director,

NCIPC, regarding feasible goals for

prevention and control of family and

intimate violence and sexual assault. The

Subcommittee will make recommendations

regarding policies, strategies, objectives and

priorities.

Matters To Be Discussed: The

Subcommittee will discuss the FY 2001

Violence Against Women activities, and

NCIPC’s Research Agenda.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Ileana Arias, Ph.D., Chief, Etiology and

Surveillance Branch (Provisional), Division

of Violence Prevention, NCIPC, CDC, 4770

Buford Highway, NE, M/S K60, Atlanta,

Georgia 30341–3724, telephone 770/488–

4410.

This notice is published less than 15

days prior to the meeting due to

administrative delays.

The Director, Management Analysis

and Services Office, has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: February 22, 2001.

John Burckhardt,

Acting Director, Management Analysis and

Services Office.

[FR Doc. 01–4828 Filed 2–27–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N–0063]

Agency Information Collection

Activities; Proposed Collection;

Comment Request; Medical Devices;

Current Good Manufacturing Practice

Quality System Regulation

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing an

opportunity for public comment on the

proposed collection of certain

information by the agency. Under the

Paperwork Reduction Act of 1995 (the

PRA), Federal agencies are required to

publish notice in the Federal Register

concerning each proposed collection of

information, including each proposed

extension of an existing collection of

information, and to allow 60 days for

public comment in response to the

notice. This notice solicits comments on

information collection requirements

related to the medical devices current

good manufacturing practice (CGMP)

quality system (QS) regulation.

DATES: Submit written comments or

electronic comments on the collection

of information by April 30, 2001.

ADDRESSES: Submit electronic

comments on the collection of

information to http://

www.accessdata.fda.gov/scripts/oc/

dockets/edockethome.cfm. Submit

written comments on the collection of

information to the Dockets Management

Branch (HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852. All

comments should be identified with the

docket number found in brackets in the

heading of this document.

FOR FURTHER INFORMATION CONTACT:

Peggy Schlosburg, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1223.

SUPPLEMENTARY INFORMATION: Under the

PRA (44 U.S.C. 3501–3520), Federal

agencies must obtain approval from the

Office of Management and Budget

(OMB) for each collection of

information they conduct or sponsor.

‘‘Collection of information’’ is defined

in 44 U.S.C. 3502(3) and 5 CFR

1320.3(c) and includes agency requests

or requirements that members of the

public submit reports, keep records, or

provide information to a third party.

Section 3506(c)(2)(A) of the PRA (44

U.S.C. 3506(c)(2)(A)) requires Federal

agencies to provide a 60-day notice in

the Federal Register concerning each

proposed collection of information,

including each proposed extension of an

existing collection of information,

before submitting the collection to OMB

for approval. To comply with this

requirement, FDA is publishing notice

of the proposed collection of

information set forth in this document.

With respect to the following

collection of information, FDA invites

comments on: (1) Whether the proposed

collection of information is necessary